Clinical trial
A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of Epaxal® With Reference to Havrix Junior® Healthy in Healthy Children and Adolescents (>=12 Months - 16 Years of Age) Using a 0/6 Month Schedule
NCT01405677 is registered in ClinicalTrials.gov with Crucell Holland BV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of Epaxal® With Reference to Havrix Junior® Healthy in Healthy Children and Adolescents (>=12 Months - 16 Years of Age) Using a 0/6 Month Schedule
- Lead sponsor
- Crucell Holland BV
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2004
- Completion date
- April 30, 2012
- Enrollment
- 308 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.